Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Gelion reports 'strong progress' with Li-ion battery recycling tech

(Sharecast News) - Anglo-Australian battery company Gelion has reported "strong progress" at its Battery Minerals division as it continues to develop its novel lithium-ion battery recycling technology. The technology in question is based on a process originally developed at chemicals giant Johnson Matthey, which was acquired by Gelion in 2023.

Following the grant and booster funding through the Advanced Propulsion Centre as announced in March, the company said it was making significant operational and technical progress.

This includes the appointment of key team personnel, including the appointment of Dr Koen Vandaele - the original inventor of the core lithium extraction patents and former Johnson Matthey technical lead - as principle scientist.

Meanwhile, a dedicated testing facility in London has been commissioned, while the team is validating key data and sample testing black mass (the granular material left behind after lithium batteries are shredded) to see how much lithium can be recovered.

Gelion also hailed the strengthening of its IP portfolio, with the recent grant of a UK patent covering the lithium extraction from black mass, while patent applications have been allowed in the US and Europe.

"This is a significant step forward for Gelion and our mission to accelerate the energy transition," said chief executive John Wood.

Shares were 3.7% higher at 24.89p by 1023 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.